| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
ORIGINAL ARTICLE |
1 Department of Health Sciences, University of York, York YO10 5DD, UK
2 NHS Centre for Reviews and Dissemination, University of York, York YO10 5DD, UK
Correspondence to:
Dr S Gilbody
Senior Lecturer in Mental Health Services Research, Department of Health Sciences, Seebohm Rowntree Building, Alcuin College, University of York YO10 5DD; sg519{at}york.ac.uk
Background: Direct to consumer advertising is increasingly used by the pharmaceutical industry, but its benefits and harms have yet to be summarised in a comprehensive and rigorous manner.
Methods: A systematic review was conducted of robust evaluations of the impact (positive and negative) of direct to consumer advertising. A broad range of databases and data sources (including Cinahl, Embase, HMIC, HSRProj, Medline, PsycInfo, and the internet) were searched from inception to 2004.
Results: From 2853 citations only four reports were found that met the strict inclusion criteria and provided usable results. Direct to consumer advertising is associated with increased prescription of advertised products and there is substantial impact on patients’ request for specific drugs and physicians’ confidence in prescribing. No additional benefits in terms of health outcomes were demonstrated.
Discussion: Direct to consumer advertising is banned in most countries, and the research evidence tends to support the negative impact that is feared by those who support a legislative ban. Further research is needed into the clinical and economic impact of direct to consumer advertising in healthcare systems.
Abbreviations: DTCA, direct to consumer advertising
Keywords: direct to consumer advertising; prescribing
This article has been cited by other articles:
|
|
 |
|
  P. Rutter and S. Gilbody The European pharmaceutical industry: coming to a screen near you? J R Soc Med, October 1, 2008; 101(10): 485 - 488. [Full Text] [PDF]
|
|
|
|
 |
|
 M. R Law, S. R Majumdar, and S. B Soumerai Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study BMJ, September 2, 2008; 337(sep02_1): a1055 - a1055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Wilson, A. M Booth, A. Eastwood, and I. S Watt Deconstructing media coverage of trastuzumab (Herceptin): an analysis of national newspaper coverage J R Soc Med, March 1, 2008; 101(3): 125 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Magrini and M. Font Direct to consumer advertising of drugs in Europe BMJ, September 15, 2007; 335(7619): 526 - 526. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Jagsi Conflicts of Interest and the Physician-Patient Relationship in the Era of Direct-to-Patient Advertising J. Clin. Oncol., March 1, 2007; 25(7): 902 - 905. [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Stange Time to Ban Direct-to-Consumer Prescription Drug Marketing Ann. Fam. Med, March 1, 2007; 5(2): 101 - 104. [Full Text] [PDF]
|
|
|
|
|
|
K. C. Stange In This Issue: Doctor-Patient and Drug Company-Patient Communication Ann. Fam. Med, January 1, 2007; 5(1): 2 - 4. [Full Text] [PDF]
|
|
|
|
 |
|
 D Klein, A MacDonald, N Drummond, and A Cave A qualitative study to identify factors influencing COXIB prescribed by family physicians for musculoskeletal disorders Fam. Pract., December 1, 2006; 23(6): 659 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Minerva BMJ, October 15, 2005; 331(7521): E392 - E392. [Full Text] [PDF]
|
|
|
|
|
|
Minerva BMJ, August 13, 2005; 331(7513): 412 - 412. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
